ClinicalTrials.gg
CompletedNCT01084161Updated Dec 2, 2011

Study to Evaluate the Efficacy, Safety and Tolerability of N1539

A Phase 2 interventional study of N1539 and N1539 in Hysterectomy, sponsored by Alkermes, Inc.. Completed at 13 sites in 3 countries. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-12-02.

Sponsored by Alkermes, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
486
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

To determine the analgesic efficacy, duration of effect, and safety of single doses of N1539 in subjects undergoing open abdominal hysterectomy

02

Conditions studied

  • Hysterectomy
03

In context

Lead sponsor

Alkermes, Inc. is the lead sponsor of 83 studies on the registry; 9 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • moderate to severe pain with VAS of >/= 45 mm
  • undergo open abdominal hysterectomy
  • signed ICF
  • >18.5 and \< 31.5 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • suspected cervical or endometrial cancer
  • prior abdominal surgery with postoperative complications
  • active pancreatitis, obstruction of biliary tree or total > 2.5 mg/dL
  • active GI bleeding, or peptic ulcer disease
  • unstable medical condition
  • >9.5 or uncontrolled diabetes
  • SBP >150 mmHg or DBP > 95 mmHg
  • personal or familial to undergoing general anesthesia
  • Antihypertensive agents or diabetic regimen that is not stable (4 weeks prior to surgery)
  • taking CNS agents for pain
  • acetaminophen or NSAIDs not discontinued for at least 5 half-lives prior to planned surgery
  • currently taking an opioid or has taken an opioid chronically for pain in past 2 years
  • or systemic corticosteroids within 6 weeks of planned surgery
  • has a known bleeding disorder or taking agents affecting coagulation
  • history of intolerance or allergic reactions to NSAIDs, COX-2 inhibitors, aspirin and other salicylates
  • receiving lithium or a combination of furosemide with an ACE inhibitor or angiotensin receptor blocker
  • Known to have sleep apnea
  • History of or C
  • or ALT > 2 times the
  • Known or suspected with retention of carbon dioxide
  • psychiatric condition that impairs the capability of the subject to report pain
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
486 participants (actual)

Study arms

  • Experimental
    N1539 5 mg

    Drug: N1539

  • Experimental
    N1539 7.5 mg

    Drug: N1539

  • Experimental
    N1539 15 mg

    Drug: N1539

  • Experimental
    N1539 30 mg

    Drug: N1539

  • Experimental
    N1539 60 mg

    Drug: N1539

  • Placebo comparator
    Placebo

    Drug: placebo

  • Active comparator
    morphine

    Drug: Morphine

Interventions

  • DrugN1539

    5 mg IV once per day

  • DrugN1539

    7.5 mg IV once per day

  • DrugN1539

    15 mg IV once per day

  • DrugN1539

    30 mg IV once per day

  • Drugplacebo

    IV placebo once per day

  • morphine 10-15 mg IV once per day

  • DrugN1539

    60 mg IV once per day

06

What researchers measure

Primary outcomes

  1. To determine the analgesic efficacy, duration of effect and safety of single doses of IV N1539 as measured by the SPID (summary of pain intensity) and TOPAR (summary of the time-weighted pain relief scores) from 0-24 hours.

    Additionally, to determine the efficacy seen within the first hour after study drug administration, as measured by the SPID 0-60 minutes post-dose.

    Time frame: at 60 minutes post dose and at 24 hours

Secondary outcomes

  1. To assess the safety and tolerability of IV N1539 by laboratory data, vital signs, wound site evaluation and Adverse Events

    Time frame: 5-7 days post initial dosing

07

Study locations

13 sites
  • Tbilisi, 0159, Georgia
  • Tbilisi, 0186, Georgia
  • Tblisi, 0186, Georgia
  • Bialystok, 15-276, Poland
  • Gdansk, 80-402, Poland
  • Lodz, 94-029, Poland
  • Lublin, 20-081, Poland
  • Poznan, 60-535, Poland
  • Ruda Slaska, 41-703, Poland
  • Szczecin, 70-111, Poland
  • Belgrade, 11000, Serbia
  • Kragujevac, 34000, Serbia
  • Novi Sad, 21000, Serbia
08

References and documents

Publications

  • Rechberger T, Mack RJ, McCallum SW, Du W, Freyer A. Analgesic Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-Severe Pain After Open Abdominal Hysterectomy: A Phase 2 Randomized Clinical Trial. Anesth Analg. 2019 Jun;128(6):1309-1318. doi: 10.1213/ANE.0000000000003920. PubMed 31094806 ↗
  • Viscusi ER, Gan TJ, Bergese S, Singla N, Mack RJ, McCallum SW, Du W, Hobson S. Intravenous meloxicam for the treatment of moderate to severe acute pain: a pooled analysis of safety and opioid-reducing effects. Reg Anesth Pain Med. 2019 Mar;44(3):360-368. doi: 10.1136/rapm-2018-100184. Epub 2019 Feb 7. PubMed 30737315 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2010
First posted
Mar 10, 2010
Start
Mar 2010
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results delay requested
Jun 24, 2011
Last update
Dec 2, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01084161
Lead sponsor
Alkermes, Inc.
Responsible party
Sponsor
First posted
Mar 10, 2010
Start date
Mar 2010
Primary completion
Jan 2011
Completion
Jan 2011
Last update
Dec 2, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion